435 related articles for article (PubMed ID: 35357449)
1. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.
Graf RP; Fisher V; Weberpals J; Gjoerup O; Tierno MB; Huang RSP; Sayegh N; Lin DI; Raskina K; Schrock AB; Severson E; Haberberger JF; Ross JS; Creeden J; Levy MA; Alexander BM; Oxnard GR; Agarwal N
JAMA Netw Open; 2022 Mar; 5(3):e225394. PubMed ID: 35357449
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden.
Quintanilha JCF; Graf RP; Fisher VA; Oxnard GR; Ellis H; Panarelli N; Lin DI; Li G; Huang RSP; Ross JS; Myer PA; Klempner SJ
JAMA Netw Open; 2023 Jan; 6(1):e2252244. PubMed ID: 36689222
[TBL] [Abstract][Full Text] [Related]
3. Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer.
Graf RP; Fisher V; Creeden J; Schrock AB; Ross JS; Nimeiri H; Oxnard GR; Klempner SJ
Cancer Res Commun; 2022 Sep; 2(9):1037-1048. PubMed ID: 36922935
[TBL] [Abstract][Full Text] [Related]
4. Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer.
Graf RP; Fisher V; Mateo J; Gjoerup OV; Madison RW; Raskina K; Tukachinsky H; Creeden J; Cunningham R; Huang RSP; Mata DA; Ross JS; Oxnard GR; Venstrom JM; Zurita AJ
Eur Urol; 2022 Jan; 81(1):37-47. PubMed ID: 34716049
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy.
Aggarwal C; Ben-Shachar R; Gao Y; Hyun SW; Rivers Z; Epstein C; Kaneva K; Sangli C; Nimeiri H; Patel J
JAMA Netw Open; 2023 May; 6(5):e2311181. PubMed ID: 37129893
[TBL] [Abstract][Full Text] [Related]
6. Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational Burden.
Necchi A; Spiess PE; Costa de Padua T; Li R; Grivas P; Huang RSP; Lin DI; Danziger N; Ross JS; Jacob JM; Sager RA; Basnet A; Li G; Graf RP; Pavlick DC; Bratslavsky G
JAMA Netw Open; 2023 Dec; 6(12):e2348002. PubMed ID: 38150257
[TBL] [Abstract][Full Text] [Related]
7. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
8. Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin Benefit in Cisplatin-Unfit Patients With Urothelial Carcinoma.
Graf RP; Fisher V; Huang RSP; Hamdani O; Gjoerup OV; Stanke J; Creeden J; Levy MA; Oxnard GR; Gupta S
JCO Precis Oncol; 2022 Aug; 6():e2200121. PubMed ID: 35977348
[TBL] [Abstract][Full Text] [Related]
9. Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness.
Quintanilha JCF; Storandt MH; Graf RP; Li G; Keller R; Lin DI; Ross JS; Huang RSP; Schrock AB; Oxnard GR; Chakrabarti S; Mahipal A
JCO Precis Oncol; 2023 Jul; 7():e2300092. PubMed ID: 37410975
[TBL] [Abstract][Full Text] [Related]
10. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors.
Manca P; Corti F; Intini R; Mazzoli G; Miceli R; Germani MM; Bergamo F; Ambrosini M; Cristarella E; Cerantola R; Boccaccio C; Ricagno G; Ghelardi F; Randon G; Leoncini G; Milione M; Fassan M; Cremolini C; Lonardi S; Pietrantonio F
Eur J Cancer; 2023 Jul; 187():15-24. PubMed ID: 37099945
[TBL] [Abstract][Full Text] [Related]
11. Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer.
Hwang C; Henderson NC; Chu SC; Holland B; Cackowski FC; Pilling A; Jang A; Rothstein S; Labriola M; Park JJ; Ghose A; Bilen MA; Mustafa S; Kilari D; Pierro MJ; Thapa B; Tripathi A; Garje R; Ravindra A; Koshkin VS; Hernandez E; Schweizer MT; Armstrong AJ; McKay RR; Dorff TB; Alva AS; Barata PC
JAMA Netw Open; 2023 Sep; 6(9):e2334208. PubMed ID: 37721753
[TBL] [Abstract][Full Text] [Related]
12. Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma.
Andrews MC; Li G; Graf RP; Fisher VA; Mitchell J; Aboosaiedi A; O'Rourke H; Shackleton M; Iddawela M; Oxnard GR; Huang RSP
JCO Precis Oncol; 2024 Jun; 8():e2300640. PubMed ID: 38848517
[TBL] [Abstract][Full Text] [Related]
13. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database.
Singal G; Miller PG; Agarwala V; Li G; Kaushik G; Backenroth D; Gossai A; Frampton GM; Torres AZ; Lehnert EM; Bourque D; O'Connell C; Bowser B; Caron T; Baydur E; Seidl-Rathkopf K; Ivanov I; Alpha-Cobb G; Guria A; He J; Frank S; Nunnally AC; Bailey M; Jaskiw A; Feuchtbaum D; Nussbaum N; Abernethy AP; Miller VA
JAMA; 2019 Apr; 321(14):1391-1399. PubMed ID: 30964529
[TBL] [Abstract][Full Text] [Related]
14. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
[TBL] [Abstract][Full Text] [Related]
15. Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors.
Xavier CB; Lopes CDH; Awni BM; Campos EF; Alves JPB; Camargo AA; Guardia GDA; Galante PAF; Jardim DL
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358851
[TBL] [Abstract][Full Text] [Related]
16. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Li Y; Ma Y; Wu Z; Zeng F; Song B; Zhang Y; Li J; Lui S; Wu M
Front Immunol; 2021; 12():751407. PubMed ID: 34659255
[TBL] [Abstract][Full Text] [Related]
17. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
Labriola MK; Zhu J; Gupta RT; McCall S; Jackson J; Kong EF; White JR; Cerqueira G; Gerding K; Simmons JK; George D; Zhang T
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221016
[TBL] [Abstract][Full Text] [Related]
18. Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes.
Loupakis F; Depetris I; Biason P; Intini R; Prete AA; Leone F; Lombardi P; Filippi R; Spallanzani A; Cascinu S; Bonetti LR; Maddalena G; Valeri N; Sottoriva A; Zapata L; Salmaso R; Munari G; Rugge M; Dei Tos AP; Golovato J; Sanborn JZ; Nguyen A; Schirripa M; Zagonel V; Lonardi S; Fassan M
Oncologist; 2020 Jun; 25(6):481-487. PubMed ID: 31967692
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patents with Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Durvalumab.
Lebow ES; Shepherd A; Eichholz JE; Offin M; Gelblum DY; Wu AJ; Simone CB; Schoenfeld AJ; Jones DR; Rimner A; Chaft JE; Riaz N; Gomez DR; Shaverdian N
JAMA Netw Open; 2023 Jan; 6(1):e2249591. PubMed ID: 36602799
[TBL] [Abstract][Full Text] [Related]
20. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
